Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hendrik Veelken

Showing results (1-10 of 145) with videos related to

Pageof 15
Sort By:
Blood|December 28, 2023
Energy overpowers sweet tooth in FLHendrik Veelken
Seminars in Cancer Biology|September 10, 2003
Active immunotherapy in follicular lymphomaHendrik Veelken
Oncology|June 18, 2002
Vaccination strategies in the treatment of lymphomasHendrik Veelken, Frank Osterroth
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Active immunotherapy of multiple myelomaLeonora Houet, Hendrik Veelken
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
IdelalisibKatja Zirlik, Hendrik Veelken
Onkologie|November 15, 2005
[Active immunotherapy in patients with hematologic and solid neoplasms]Håkan Mellstedt, Hendrik Veelken
Immunotherapy|July 20, 2010
Dendritic-cell vaccination for prostate cancerAnna-Katharina Thomas-Kaskel, Hendrik Veelken
Pharmazie in Unserer Zeit|April 29, 2010
[Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors]Katja Zirlik, Dorothée Nashan, Hendrik Veelken
Onkologie|June 1, 2011
Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphomaLaura Debatin, Annette Schmitt-Graeff, Hendrik Veelken
The Lancet. Oncology|November 30, 2020
COVID-19 and systemic anticancer therapy: exploiting uncertaintyHans Gelderblom, Hendrik Veelken, Anne M Stiggelbout
Pageof 15

Showing results (1-10 of 145) with videos related to

Sort By:
Pageof 15
Blood|December 28, 2023
Energy overpowers sweet tooth in FLHendrik Veelken
Seminars in Cancer Biology|September 10, 2003
Active immunotherapy in follicular lymphomaHendrik Veelken
Oncology|June 18, 2002
Vaccination strategies in the treatment of lymphomasHendrik Veelken, Frank Osterroth
European Journal of Cancer (Oxford, England : 1990)|June 27, 2006
Active immunotherapy of multiple myelomaLeonora Houet, Hendrik Veelken
Recent Results in Cancer Research. Fortschritte Der Krebsforschung. Progres Dans Les Recherches Sur Le Cancer|August 3, 2018
IdelalisibKatja Zirlik, Hendrik Veelken
Onkologie|November 15, 2005
[Active immunotherapy in patients with hematologic and solid neoplasms]Håkan Mellstedt, Hendrik Veelken
Immunotherapy|July 20, 2010
Dendritic-cell vaccination for prostate cancerAnna-Katharina Thomas-Kaskel, Hendrik Veelken
Pharmazie in Unserer Zeit|April 29, 2010
[Vorinostat in the treatment of cutaneous T-cell lymphomas. Treatment with histone deacetylases inhibitors]Katja Zirlik, Dorothée Nashan, Hendrik Veelken
Onkologie|June 1, 2011
Rapid-onset, prolonged bone marrow failure following rituximab therapy of follicular lymphomaLaura Debatin, Annette Schmitt-Graeff, Hendrik Veelken
The Lancet. Oncology|November 30, 2020
COVID-19 and systemic anticancer therapy: exploiting uncertaintyHans Gelderblom, Hendrik Veelken, Anne M Stiggelbout
Pageof 15